Unilife Corporation 2010 fourth quarter revenue increases to $2.7 million

Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced preliminary financial results for the fourth quarter and fiscal year ended June 30, 2010.

Mr. Alan Shortall, Chief Executive Officer of Unilife said: "Fiscal 2010 has been a pivotal year for Unilife, as we completed several major milestones including the redomiciliation of the Company to the U.S. and our listing on NASDAQ."

"We have also expanded our executive team and board of directors to reflect our U.S. expansion.  Each person brings to the company specific skills and experience that will help guide us through what we expect to be an extremely busy and exciting next couple of years."

"We are now working to finalize the industrialization of the Unifill™ syringe and expand relationships with interested pharmaceutical companies, accelerate the global rollout of our Unitract 1mL syringes; and complete the construction of our new state-of-the-art facility in York, Pennsylvania. We remain committed to the continued implementation of our business strategy, and the execution of a number of significant business milestones during fiscal 2011."

Annual Company Highlights:

• Redomiciled the Company to the U.S. (January 2010).
• Unilife Corporation common stock listed on the NASDAQ stock exchange (February 2010).
• Signed an industrialization agreement with sanofi-aventis (July 2009), followed by an agreement between both parties to a list of therapeutic classes including vaccines and anti-thrombotic agents where sanofi-aventis has exclusive rights to negotiate the purchase of the Unifill syringe until June 2014 (March 2010).
• Appointed the Mikron Group as the contracted supply partner for the development and supply of automated assembly systems to support the commercial production of the Unifill™ syringe (November 2009).
• Initiated U.S. production of the Unitract 1mL Insulin Syringe in Lewisberry, Pennsylvania (PA) (August 2009), and the subsequent first shipment of the product to Doctors Without Borders to support relief efforts in Haiti.
• Received U.S. FDA market clearance for the Unitract 1mL Insulin Syringes assembled in Lewisberry, PA (April 2010), and the provision of EC certification for the European Union and Australia (June 2010).
• Signed distribution agreements for the Unitract 1mL syringes, including an agreement with Stason Pharmaceuticals Inc for Japan, China and Taiwan (March 2010); and an agreement with Clinicare for India (April 2010).
• Started construction on new global headquarters and commercial production facility in York, PA (December 2009).  The new 165,000 square foot state-of-the-art facility is on schedule for operations by late-2010.
• Following the signing of the Industrialization Agreement, Unilife was able to commence discussions with other pharmaceutical companies interested in the use of the Unifill™ syringe within therapeutic drug classes outside of those retained by sanofi-aventis.  A number of these discussions have accelerated during the past year.
• Appointed additional U.S. based Board members, including Mary Kate Wold, Marc Firestone and John Lund, as well as the appointment of senior executives including CFO and Executive Vice President Richard Wieland and General Counsel, Corporate Secretary and Chief Compliance Officer Chris Naftzger.

Preliminary Financial Results for Fourth Quarter and Fiscal Year Ended June 30, 2010

Revenues for the fourth quarter ended June 30, 2010 were $2.7 million compared to $7.7 million for the same period in 2009.  Revenues for the fiscal year ended June 30, 2010 were $11.4 million compared to $20.0 million for the same period in 2009.  The decrease was primarily attributable to a relative decline in revenues from the Company's industrialization agreement with sanofi-aventis in 2010, due to the accelerated receipt of milestone payments during 2009 because the industrialization program was running ahead of its original schedule.  The Company has elected to prioritize its activities on the development and supply of its proprietary range of safety syringes. It has consequently reduced its business activities within the medical device contract manufacturing sector during this period.

The Company's net loss for the fourth quarter ended June 30, 2010 was $9.7 million or $0.18 per diluted share, compared to net income of $2.2 million, or $0.06 per diluted share for the same period in 2009.  The Company's net loss for the fiscal year ended June 30, 2010 was $29.7 million or $0.64 per diluted share, compared to a net loss of $0.5 million, or $0.02 per diluted share for the same period in 2009.  The increase in the net loss was attributable to both the decline in revenues as well as higher payroll and related expenses due to an increase in the workforce at the Lewisberry, PA facility. The Company also incurred an increase in legal and consulting fees in connection with its redomiciliation to the United States.  

Adjusted net loss for the fourth quarter ended June 30, 2010, which excludes approximately $4.0 million in share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $5.7 million, or $0.11 per diluted share compared to adjusted net income of $3.0 million or $0.08 per diluted share for the same period in 2009.  Adjusted net loss for the fiscal year ended June 30, 2010, which excludes approximately $15.2 million in share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with the redomiciliation and Nasdaq listing was $14.5 million, or $0.31 per diluted share compared to adjusted net income of $3.9 million or $0.11 per share for the same period in 2009.

As of June 30, 2010, the Company's cash and cash equivalents were $20.8 million.

The financial data included in this press release is based on preliminary unaudited information and may be subject to change. The Company expects to file its audited results for the fiscal year ended June 30, 2010 on Form 10-K with the Securities and Exchange Commission on September 28, 2010.